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AMP-activated protein kinase (AMPK) plays an important
role in controlling energy homeostasis and is envisioned as a
promising target to treat metabolic disorders. In the heart,
AMPK is involved in short-term regulation and in transcrip-
tional control of proteins involved in energy metabolism.
Here, we investigated whether deletion of AMPK2, the main
cardiac catalytic isoform, alters mitochondrial function and
biogenesis. Body weight, heart weight, and AMPK1 expres-
sion were similar in control littermate and AMPK2
/ mice.
Despite normal oxygen consumption in perfused hearts, max-
imal oxidative capacity, measured using saponin permeabil-
ized cardiac ﬁbers, was 30% lower in AMPK2
/ mice with
octanoate, pyruvate, or glutamate plus malate but not with
succinate as substrates, showing an impairment at complex
I of the respiratory chain. This effect was associated with a
25% decrease in mitochondrial cardiolipin content, the
main mitochondrial membrane phospholipid that is crucial
for complex I activity, and with a 13% decrease in mito-
chondrial content of linoleic acid, the main fatty acid of
cardiolipins. The decrease in cardiolipin content could be
explained by mRNA downregulation of rate-limiting en-
zymes of both cardiolipin synthesis (CTP:PA cytidylyl-
transferase) and remodeling (acyl-CoA:lysocardiolipin
acyltransferase 1). These data reveal a new role for
AMPK2 subunit in the regulation of cardiac muscle oxi-
dative capacity via cardiolipin homeostasis. Diabetes 56:
786–794, 2007
A
MP-activated protein kinase (AMPK) signaling
pathway plays an important role in controlling
energy homeostasis at the whole-body level by
responding to hormonal or nutrient signals in
the central nervous system and peripheral tissues that
modulate food intake and energy expenditure (1,2). AMPK
is an ubiquitous serine/threonine protein kinase activated
by pathological stimuli, such as oxidative damage, osmotic
shock, hypoxia, and glucose deprivation, and by physio-
logical stimuli, such as exercise, muscle contraction, and
hormones, including leptin and adiponectin (3). It exists in
cells as a heterotrimeric complex composed of a catalytic
subunit () and two regulatory subunits ( and ). Two
-subunit isoforms exist, 1 and 2; 2 is the chief isoform
expressed in striated muscle, accounting for 70–80% of
the total AMPK catalytic activity in this tissue (4,5).
Activation of AMPK causes upregulation of ATP-producing
catabolic pathways and downregulation of ATP-consum-
ing processes (3,6). It is activated in response to decreased
cellular energy charge (high AMP-to-ATP ratio) and is
involved in regulating carbohydrate and fat metabolism
(3,5). AMPK acutely modulates mitochondrial oxidative
ﬂux via phosphorylation of acetyl CoA carboxylase, de-
creasing malonyl-CoA levels, and increasing oxidative ﬂux
through the mitochondrial carnitine palmitoyl transferase
1 (CPT-1) (1–3,5). It also increases glucose transport (7)
and stimulates glycolysis by activating phosphofructoki-
nase 2 (8). As such, it is envisioned as a promising target
to treat metabolic disorders such as metabolic syndrome,
obesity, and type 2 diabetes.
Such patients have increased susceptibility to cardiovas-
cular disorders. The role of AMPK in the heart is not fully
understood. Whereas AMPK is activated during pressure
overload and exercise-induced hypertrophy (9,10), it me-
diates the antihypertrophic effects of adiponectin (11).
AMPK is involved in regulating carbohydrate and fatty acid
transport notably during cardiac ischemia and reperfusion
(5,8,12,13). Because the ﬁnal steps of carbohydrate and
lipid oxidation take place in mitochondria, it is very
probable that this enzyme also plays a role in mitochon-
drial substrate oxidation pathways.
AMPK can also affect energy metabolism through changes
in gene expression. It is involved in skeletal muscle
adaptation to exercise by increasing the expression of the
peroxisome proliferator–activated receptor- coactiva-
tor-1 (PGC-1) and activating mitochondrial biogenesis,
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786 DIABETES, VOL. 56, MARCH 2007but again, nothing is known concerning cardiac muscle
(14). The aim of the present study was to investigate the
possible involvement of AMPK in the control of cardiac
mitochondrial function and biogenesis using speciﬁc
AMPK2-deﬁcient mice (15). These mice exhibit normal
echocardiographic and hemodynamic characteristics but
have altered glucose metabolism and a worse metabolic
adaptation to ischemia (16).
RESEARCH DESIGN AND METHODS
The generation of AMPK2
/ mice has been described elsewhere (15).
Ten-month-old male AMPK2
/ (n  27) and control (n  25) littermate
mice were used. Animals were housed under temperature-controlled condi-
tions (21°C) and had free access to water and to a standard mouse chow. All
procedures were performed in accordance with the principles and guidelines
established by the European Convention for the Protection of Laboratory
Animals. Mice were killed by lethal intraperitoneal injection of pentothal (150
mg/kg) for mitochondrial respiration experiments and tissue storage. Left
ventricular tissue was isolated, part of which was immediately used for
mitochondrial function measurement and part of which was rapidly frozen
and kept at 80°C.
Perfused hearts. Additional mice were anesthetized with urethane (2 g/kg).
Hearts were quickly removed and retrogradely perfused at a constant ﬂow of
2.5 ml/min in the isovolumic Langendorff perfused mode without pacing. They
were ﬁrst equilibrated with 11 mmol/l glucose for 30 min and then with 5
mmol/l glucose and 0.4 mmol/l oleate prebound to 1% BSA as substrates for 20
more min. Left ventricular pressure was monitored from a water-ﬁlled balloon
introduced in the left ventricle. Oxygen consumption (QO2) was calculated
from the difference in oxygen content between incoming (aortic) and outcom-
ing (pulmonary artery) perfusates (17).
Electron microscopy. Left ventricular wall and papillary muscles were
quickly isolated in oxygenated buffered Krebs solution without calcium to
avoid ischemia and ﬁxed with 2% glutaraldehyde as previously described (18).
For stereological analysis, papillary muscles were used to ensure longitudinal
sections, and three randomly selected levels separated by 50 m were used.
From randomly selected cardiomyocytes (12–14 myocytes from each animal),
the volume density of organelles was estimated by the point counting method
(18). The volume density Vv of the organelles was estimated as Vv  p/P (p is
the number of the test points hitting the image of the cellular components, P
is the number of all points falling on the cardiomyocytes).
Study of in situ mitochondrial respiration. Oxygen consumption measure-
ments of saponin-skinned ﬁbers from left ventricle have been described
previously (19,20). Rates of respiration are given in micromoles O2 per minute
per gram dry weight.
Two different experimental protocols were used based on substrate
utilization pathways (Fig. 1). The ﬁrst protocol determined the sensitivity
of mitochondrial respiration to various substrates in the presence of 2
mmol/l ADP, by cumulative substrate addition as described previously
(21). The second protocol was aimed at determining the dependency of
respiration on external [ADP] and [creatine] (22), with glutamate plus malate
as substrates. Respiration through complex III was designed according to Ray
et al. (23).
Biochemical studies. Frozen tissue samples were weighed and homogenized
in ice-cold buffer, and enzyme activities were determined as described
previously (24). Complex I activity was measured in heart homogenized in
ice-cold buffer containing 10 mmol/l Tris base (pH 7.2), 75 mmol/l sucrose, 225
mmol/l mannitol, 100 mol/l EDTA, and 0.1% Triton-X 100. To measure
NADH–coenzyme Q reductase activity with decyl-ubiquinone as electron
acceptor, samples were incubated in 25 mmol/l phosphate buffer (pH 7.5), 2.5
mg/ml BSA, and 100 mol/l decyl-ubiquinone at 30°C. Activity was reported as
rotenone-insensitive decrease in NADH absorbance at 340 nm. NADH-ferri-
cyanide reductase activity was measured with ferricyanide as electron accep-
tor, and the decrease in absorbance was followed at 410 nm.
Real-time quantitative RT-PCR analysis. Total muscle RNA was extracted
using standard procedures. Real-time RT-PCR was performed using the SYBR
Green method on a LightCycler rapid thermal cycler (Roche Diagnostics) as
previously described (25). Values of each gene were normalized to cyclophilin
A mRNA content and then corrected for the amount of RNA relative to muscle
weight. Primers are listed in Table 1.
Western blot analysis. Speciﬁc antibodies were used to measure the protein
content of the oxoglutarate/malate carrier (OMC) (26) (gift from Thomas
Scholz and Stacia Koppenhafer, University of Iowa), AMPK1, and AMPK2
(Upstate Biotechnology, Lake Placid, NY) in control and AMPK2
/ mice.
Mitochondrial isolation and cardiolipin quantiﬁcation. Mitochondria
were isolated from cardiac ventricles of control and AMPK2
/ mice according
to Moreno-Sanchez et al. (27). Cardiolipin was quantiﬁed by the spectrophoto-
metric method of Petit et al. (28), using the high afﬁnity of 10N-nonyl acridine
orange (NAO) for cardiolipin of freshly isolated mitochondria.
Fatty acid composition. Lipids were extracted from heart, isolated cardiac
mitochondria, liver, and plasma in 2:1 chloroform:methanol. Phospholipids
were separated from nonphosphorous lipids on silica acid cartridges, and
fatty acids were trans-methylated with BF3-methanol. Methyl esters were
analyzed by gas chromatography on an Econo-cap EC-WAX capillary column
(0.32 	 30 m; Alltech Associates) coupled to a ﬂame ionization detector using
C17:0 as the internal standard as previously described (29).
Statistical analysis. Data are expressed as means 
 SE. Student’s t test was
used to determine the statistical signiﬁcance of differences between group
means. Statistical signiﬁcance was deﬁned as P  0.05.
FIG. 1. Substrate utilization by cardiac mitochondria. Pyruvate enters the Krebs cycle by pyruvate dehydrogenase (PDH), producing acetyl-CoA
(Ac-CoA). Octanoyl-carnitine undergoes -oxidation and produces acetyl-CoA, NADH, and FADH2. Malate enters mitochondria through OMC and
produces mainly NADH by mitochondrial MDH (mMDH), whereas G3P produces FADH2 by the mitochondrial glycerol-phosphate dehydrogenase
(mGDH). Succinate produces mainly FADH2 that enters the respiratory chain through complex II. NADH is reoxidized in the respiratory chain
at complex I and FADH2 at complex II.
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General characteristics and baseline cardiac func-
tion. AMPK2
/ mice had normal body (32 
 1i n
control vs. 37 
 3 g) and heart (187 
 8 in control vs.
197 
 16 mg) weights, indicating that cardiac atrophy or
hypertrophy were not present. Neither left ventricular
pressure or heart rate nor oxygen consumption of isolated
hearts differed between control and AMPK2
/ mice
whether glucose or glucose plus oleate were used as
substrates, suggesting that AMKP2 deﬁciency does not
alter cardiac work during normal perfusion (Table 2).
AMPK1 protein content (as measured by Western
blotting; not shown) was the same in control and
AMPK2
/ mice (1.24 
 0.12 in control vs. 1.49 
 0.21
arbitrary units [AU]). Thus the deﬁciency in AMPK2 was
not compensated for by AMPK1 overexpression.
Ultrastructure of the cardiomyocytes. In control car-
diomyocytes, mitochondria formed longitudinal rows un-
der sarcolemma and between myoﬁbrils (Fig. 2A and B). In
contrast, in AMPK2
/ cardiomyocytes from both papil-
lary and ventricular muscles, splitting of myoﬁbrils was
frequently observed (Fig. 2C–F). No change in total mito-
chondrial volume was observed (Table 3), but mitochon-
dria lost their ellipsoid shape and became irregular in size
(Fig. 2C–F). They lost their arrangement in longitudinal
rows and formed large and spread clusters especially
under the sarcolemma (Fig. 2D and F), so that the volume
density of subsarcolemmal mitochondria was increased
while that of intermyoﬁbrillar mitochondria was de-
creased (Table 3). No change in the volume of lipid
droplets was observed (0.97 
 0.22 in control vs. 0.79 

0.61%).
Cardiac mitochondrial function. Respiration rates for
almost all substrates were signiﬁcantly lower in cardiac
ﬁbers of AMPK2
/ mice (Fig. 3A). Compared with
controls, respiration was decreased by 35% with malate,
34% after addition of octanoyl-carnitine, 38% after addition
of pyruvate, and 31% after ﬁnal addition of glutamate in
AMPK2
/ mice, but it did not change with glycerol-3-
phosphate (G3P).
Respiration in the presence of phosphate acceptors ADP
and creatine was studied with glutamate plus malate
(Vglumal) as substrates (Table 3). Basal respiration rate
(V0) and acceptor control ratio (ACR  Vglumal/V0) were
similar in control and AMPK2
/ cardiac ﬁbers. No
difference was observed between the two groups for the
afﬁnity for ADP with or without creatine. The maximal
oxygen consumption rate was again 24% lower with gluta-
mate plus malate in the AMPK2
/ mice (Table 3; Fig. 3).
To determine at which point the respiratory chain was
altered in AMPK2
/ mice, complex I was inhibited by
amobarbital, and respiration through complex II was mea-
sured with succinate (Vsuc). Under succinate, no signiﬁ-
cant difference between the two groups was observed,
whereas the ratio between complex I– and complex II–
stimulated respiration (Vsuc/Vglumal) was increased by
42% in AMPK2
/ mice (Table 3; Fig. 3B). No difference
was observed for complex III–activated respiration with
duroquinol (Vduroq). Thus, AMPK2 deﬁciency induces a
TABLE 1
Primers used for real-time PCR ampliﬁcation
Gene GenBank accession no. Primer (5–3) PCR product size (bp)
PGC-1 NM_008904 Forward: CACCAAACCCACAGAGAACAG
Reverse: GCAGTTCCAGAGAGTTCCACA 210
CDS2 NM_138651 Forward: CGGTTCATCTCCTTTGCCC
Reverse: GATGACGCACGAGATGGGA 201
CPT-1 NM_009948 Forward: TCACCTGGGCTACACGGAGA
Reverse: TCGGGGCTGGTCCTACACTT 219
TAZ NM_181516 Forward: TTGGACGGCTGATTGCTGAG
Reverse: TGTGAGGGCTTTCCGCATCT 215
ALCATI NT_039658 Forward: GGAAGTGGAAGGATGATAAG
Reverse: GTTTGAGGGATGTTGTAAGG 286
CycA NM_017101 Forward: GAGCACTGGGGAGAAAGGAT
Reverse: CTTGCCATCCAGCCACTCAG 259
CycA, cyclophilin A; TAZ, taffazin.
TABLE 2
Functional data
Wild type (n  5) aMPK2
/ (n  5)
Glucose Glucoseoleate Glucose Glucoseoleate
Ventricular pressure (mmHg) 87 
 7 109 
 78 5 
 5 118 
 6
Heart rate (beats/min) 358 
 18 317 
 17 365 
 9 337 
 16
RPP (10
4 mmHg  beats
1  min
1) 2.9 
 0.1 3.2 
 0.1 2.9 
 0.2 3.6 
 0.2
DP/dt (mmHg/s) 3,818 
 229 4,088 
 264 3,778 
 356 4,533 
 465
DP/dt (mmHg/s) 2,719 
 187 3,053 
 131 2,513 
 153 3,167 
 141
QO2 (mol O2  min
1  g
1 wet wt) 6.4 
 0.7 8.6 
 0.7* 6.0 
 0.6 8.0 
 1.0
QO2/RPP 2.3 
 0.3 2.7 
 0.3 2.1 
 0.3 2.3 
 0.3
Data are means 
 SE. n, number of mice. Hearts were ﬁrst perfused with glucose 11 mmol/l and then with glucose 5 and 0.4 mmol/l oleate.
DP/dt, developed pressure per unit time; RPP, rate pressure product; QO2, oxygen consumption rate. No statistical difference between control
and AMPK2
/.* P  0.05, glucose vs. glucose  oleate.
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complex I.
Energy metabolism enzymes. To understand the origin
of mitochondrial defects, activities of key enzymes of
energy metabolism were assessed (Table 3). Activity of
citrate synthase, an index of mitochondrial mass, was
similar in the two groups of mice. Other enzymes of the
energy metabolism, total creatine kinase (CK), mitochon-
drial CK (mi-CK), adenylate kinase, total lactate dehydro-
genase, and cytochrome c oxidase (COX) activities also
remained unchanged in AMPK2
/. Despite decreased
respiration through complex I, maximal complex I and
complex II activities determined in tissue extracts were
the same in both groups. To ensure that maximal complex
I activity was preserved in AMPK2
/, we measured its
activity using different electron acceptors, but no differ-
ence between the two groups was observed, suggesting
that AMPK deﬁciency did not affect mitochondrial enzyme
content.
In an attempt to understand the origin of the decreased
respiration through complex I, malate-aspartate shuttle
enzymes were measured (Table 3). Total malate dehydro-
genase (MDH), mitochondrial MDH, and the amount of
OMC (6.8 
 1.2 [n  6] in control vs. 5.1 
 0.5 AU in
AMPK2
/ [n  6]; not shown) were unchanged in
AMPK2-deﬁcient mice. Moreover, the mRNA levels of
FIG. 2. Electron microscopic images of left ventricle and papillary muscles from control (A and B) and AMPK2
/ (C–F) mice. A: Overview of
a control myocyte in longitudinal section, with mitochondria and myoﬁbrils arranged in regular longitudinal columns. C and E: Longitudinal
section of cardiomyocytes from papillary (C) and ventricular (E) muscles from AMPK2
/ mice showing myoﬁbrillar disorganization and
irregular arrangement of intermyoﬁbrillar mitochondria with clusters of mitochondria of variable size. B: Detail of sarcomeres in a control
myocyte, showing mitochondria tightly packed along sarcomeres. D and F: Details of sarcomeres in AMPK2
/ myocytes from papillary (D) and
ventricular (F) muscles, showing dense packing of mitochondria of irregular size. Asterisk, large mitochondria having irregular shape. Arrows,
splitting of myoﬁbrils. Arrowhead, dividing mitochondrion.
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were similar in AMPK2
/ and control hearts (Fig. 4B),
consistent with the preserved mitochondrial enzyme
activities.
Cardiolipins and fatty acid composition. Complex I
activity in situ is critically dependent on the cardiolipin
environment (30,31). In AMPK2
/ mice, the amount of
cardiolipin was 25% lower than in controls (Fig. 4A). In
addition, as evidenced in Table 4, the fatty acid composi-
tion of whole-heart phospholipids and of isolated cardiac
mitochondria in the AMPK2
/ mice showed a signiﬁcant
decrease in linoleic acid proportion (80% of cardiolipin
fatty acids). Conversely, linoleic acid was signiﬁcantly
increased in the nonphosphorous lipid fraction (which
mainly contains storage triacylglycerol) of the whole-heart
homogenate. This decrease in linoleic acid content was
speciﬁc to the heart because it decreased neither in liver
phospholipids (19.4 
 0.8 and 19.6 
 1.1%, control vs.
AMPK2
/) nor in plasma lipids (31.3 
 0.4 and 27.8 

2.2%, respectively).
The level of expression of enzymes involved in cardio-
lipin homeostasis was determined (Fig. 4B). Levels of
CTP:PA cytidylyltransferase (CDS2), the enzyme that cat-
alyzes the initial key step of cardiolipin synthesis, i.e., the
conversion of phosphatidic acid to CDP-diacylglycerol,
and of acyl-CoA:lysocardiolipin acyltransferase 1 (AL-
CAT1), which is implicated in rapid cardiolipin remodeling
(32,33), were signiﬁcantly decreased in AMPK2
/ mice,
whereas mRNA content of taffazin, another phospholipid
acyltransferase, was unchanged. Interestingly, expression
of CPT-1, the mitochondrial middle- and long-chain fatty
acid transporter, was also signiﬁcantly decreased in
AMPK-deﬁcient mice.
DISCUSSION
The main results of this study can be summarized as
follows. 1) Speciﬁc deﬁciency in AMPK2 catalytic sub-
unit did not induce cardiac atrophy or hypertrophy. 2)
Oxygen consumption of isolated perfused heart was nor-
mal, but mitochondrial ultrastructure was altered. 3)
AMPK deﬁciency induced a decrease in maximal oxidative
capacity of the cardiac muscle whether lipids, pyruvate, or
glutamate plus malate were used as substrates. 4) This
was not accompanied by changes in mitochondrial enzyme
activities, the malate/aspartate shuttle, or isolated com-
plex I or II in vitro activities. 5) When succinate was used
as substrate, mitochondrial respiration was normal in
AMPK2
/ cardiac ﬁbers, suggesting a defect in complex
TABLE 3
Energy metabolism of cardiac ﬁbers
Control AMPK2
/
Morphometric data
Hearts (n)3 3
Total mitochondria 36.1 
 1.8 37.6 
 0.5
SS mitochondria 3.9 
 0.4 11.3 
 1.1*
IM mitochondria 32.2 
 1.4 26.3 
 1.4*
Mitochondrial function
Fibers (n)2 0 1 8
V0 (mol O2  min
1  g
1 dry wt) 3.0 
 0.3 2.7 
 0.2
Vglumal (mol O2  min
1  g
1 dry wt) 18 
 11 3 
 1*
Vsuc (mol O2  min
1  g
1 dry wt) 19 
 22 3 
 2
Vsuc/Vglumal 1.2 
 0.1 1.7 
 0.2*
V
duroq (mol O2  min
1  g
1 dry wt)* 50 
 10 54 
 8
KmADP 253 
 54 289 
 49
KmCr 73 
 14 52 
 11
ACR 6.2 
 0.9 4.9 
 0.4
Enzymatic activity (IU/mg protein)
Animals (n)9 8
Citrate synthase 836 
 58 742 
 48
Cytochrome oxidase 1,207 
 120 1,114 
 114
CK 2,637 
 182 2,860 
 171
mi CK 653 
 96 716 
 67
Adenylate kinase 2,107 
 150 2,414 
 219
Lactate dehydrogenase 932 
 75 999 
 70
Complex 1 (decyl-ubiquinone) 450 
 64 413 
 51
Complex I (ferricyanure) 990 
 86 914 
 77
Complex II 264 
 27 226 
 21
MDH 5,906 
 500 5,843 
 573
Mitochondrial MDH 1,913 
 250 1,818 
 112
Data are means 
 SE. Morphological data are expressed in percent
cell volume. Oxygen consumption rates in the absence (V0) and
presence of 2 mmol/l ADP (Vglumal, respiration through complex I
with glutamatemalate; Vsuc, respiration through complex II with
succinate; Vduroq, respiration through complex III with reduced
duroquinol). *n  10 for each. Michaelis-Menten constant of respi-
ration rate for ADP (mol/l) without (Km) or with (KmCr) 20 mmol/l
creatine. ACR, acceptor control ratio (Vglumal/V0). IM, intermyoﬁ-
brillar; SS, subsarcolemmal. *P  0.05 vs. control mice.
FIG. 3. A: Decreased substrate utilization by cardiac mitochondria in
AMPK2
/ mice. Respiration rates were measured during the cumu-
lative addition of substrates in saponin-skinned cardiac ﬁbers of
control and AMPK2
/ mice. Vo2, rate of O2 consumption in micro-
moles per minute per gram dry weight. Glu, glutamate; Mal, malate;
Oct, octanoyl-carnitine; Pyr, pyruvate. *P < 0.05 vs. control. B: Respi-
ration rate through complex I is speciﬁcally inhibited in AMPK2
/
mouse heart. VO2, rate of O2 consumption in micromoles per minute per
gram dry weight in saponin-permeabilized cardiac ﬁbers. Complex I,
respiration with 2 mmol/l malate and 5 mmol/l glutamate. Complex II,
respiration with 10 mmol/l succinate. *P < 0.05 vs. control.
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/
cardiac mitochondria was decreased by 25%, consistent
with the altered ultrastructure and the functional defect of
mitochondrial respiration by complex I. 7) This defect was
accompanied by a signiﬁcant decrease in linoleic acid
content of mitochondrial phospholipids and 8) could be
explained by the decrease in the expression of key en-
zymes of cardiolipin biosynthesis and remodeling. Alto-
gether, these results suggest that AMPK2 is involved in
the control of mitochondrial respiration through cardio-
lipin homeostasis.
AMPK2
/ mice exhibit perturbation in whole-body
insulin sensitivity, probably modulated by the sympathetic
nervous system (15). These mice show normal cardiac
content in AMPK1 isoform, suggesting that remnant
AMPK1 is unable to compensate for the lack of AMPK2
(16).
A role for AMPK in controlling cardiac weight is still
controversial. Although AMPK was suggested to play a
role in pressure overload hypertrophy (9), it was recently
reported that adiponectin blocks cardiac hypertrophy by
an AMPK-dependent mechanism (11). Hearts of mice
expressing a dominant-negative mutant of AMPK2 exhib-
iting a residual AMPK2 activity have preserved weight
and baseline function (13). In another model overexpress-
ing a kinase-dead rat 2 isoform, the 2 protein content
and activity were absent, and 1 content and activity were
also decreased, with the remnant 1 activity being attrib-
uted to endothelial cells (12). These mice exhibit a slightly
decreased cardiac weight and contractility. However, we
show here that AMPK2
/ mice had normal cardiac
weight. This suggests that the 2 subunit by itself is not
essential for cardiac growth.
Oxygen consumption and contractile function were not
different under basal conditions either with glucose or
glucose plus oleate as substrates, as already described
with glucose and pyruvate (16) in this mouse line. In KD
mutant mice, cardiac function is slightly depressed at
baseline (12). This difference could be due to the de-
creased AMPK1 activity in this line. However, the work-
load of hearts perfused in the Langendorff mode is
signiﬁcantly less than in the working mode or in vivo, and
oxygen consumption does not reach maximal capacity.
To assess maximal mitochondrial function, respiration
rates were measured in skinned ﬁbers with saturating
amounts of substrates, oxygen, and phosphate acceptor.
FIG. 4. A: Cardiolipin content is decreased in AMPK2
/ mice mito-
chondria. Data obtained by colorimetric assay with the NAO in cardiac
muscle of AMPK2
/ (n  6) and littermate (n  6) mice in nano-
moles per milligram mitochondrial proteins. *P < 0.05 vs. control. B:
Gene expression. Real-time quantitative RT-PCR analysis of mRNA
expression of PGC-1, CDS2, CPT-1, tafazzin (TAZ), and ALCAT1 in
cardiac muscle of AMPK2
/ (n  6) and littermate (n  6) mice.
Results are given as means  SE in AU normalized to Cyclophilin A
transcription and corrected for the amount of total RNA relative to
muscle weight.
TABLE 4
Fatty acid composition of cardiac lipids
Fatty acid
Composition
Heart mitochondria Heart phospholipids Nonphosphorous lipids
Control AMPK2
/ Control AMPK2
/ Control AMPK2
/
16:0 13.4 
 0.6 14.6 
 0.7 14.2 
 0.9 16.4 
 0.5 19.8 
 0.5 18.1 
 0.4
16:19 1.1 
 0.2 1.0 
 0.3 0.3 
 0.1 0.35 
 0.03 6.2 
 0.7 4.5 
 0.3
18:0 18 
 11 7 
 12 1 
 12 1 
 1 8.9 
 0.3 9 
 1
18:19 6.7 
 0.3 7.0 
 0.2 6.3 
 0.3 6.3 
 0.3 19.0 
 0.4 22.0 
 0.4*
18:17 2.51 
 0.03 2.7 
 0.1 2.26 
 0.04 2.5 
 0.1 1.4 
 0.1 1.5 
 0.3
18:26 LA 19.2 
 0.6 16.8 
 0.4* 18.0 
 0.2 16.3 
 0.5* 20.1 
 1.5 24.3 
 0.3*
20:46 4.5 
 0.2 4.3 
 0.2 5.2 
 0.2 4.9 
 0.3 3.0 
 0.1 2.6 
 0.4
22:53 1.02 
 0.03 1.2 
 0.1 1.1 
 0.1 4.1 
 3.1 1.5 
 0.1 1.5 
 0.4
22:633 0 
 23 1 
 22 8 
 22 4 
 1 5.1 
 0.4 5.4 
 0.6
SFA 32 
 13 3 
 13 6 
 23 4 
 53 6 
 13 9 
 5
MUFA 12 
 11 1 
 1 9.7 
 0.3 9 
 13 1 
 13 6 
 6
PUFA6 25.1 
 0.5 22.5 
 0.6* 25.2 
 0.4 20 
 32 5 
 13 3 
 5
PUFA33 1 
 23 3 
 22 9 
 22 4 
 4 8.1 
 0.3 9 
 1
Data are means 
 SE (%). LA, linoleic acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid.
Three control and three AMPK2
/ mice were used. *P  0.05.
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mitochondria are able to use acetyl-CoA produced from
pyruvate by pyruvate dehydrogenase downward of glyco-
lysis and/or acetyl-CoA produced by the -oxidation of
fatty acids, which enters the Krebs cycle (Fig. 1). Mito-
chondria can also slightly use G3P by mitochondrial
glycerophosphate dehydrogenase, which produces re-
duced ﬂavine adenine dinucleotide (FADH2) that enters
the respiratory chain directly at the level of complex II
(34). We found a clear decrease in the respiration rate of
AMPK2
/ cardiac ﬁbers, whether carbohydrate- or lipid-
derived substrates were used. This suggests that AMPK2
is involved in the control of cardiac oxidative capacity and
in mitochondrial substrate utilization. Decreased energy
availability in AMPK2
/ mice would probably occur
only at maximal workloads, so that the mitochondrial
alterations observed here might be more evident during
heavy exercise or under pathologic stress.
To understand the decrease in respiration of cardiac
ﬁbers, we looked at indicators of mitochondrial activity. In
AMPK2
/ mouse heart, levels of citrate synthase, a
marker of mitochondrial mass; of COX, an enzyme of the
respiratory chain; of mi-CK, a phosphotransfer kinase; and
of markers of the malate/aspartate shuttle, which are
involved in glutamate plus malate utilization, were normal.
Additionally, PGC-1, which induces mitochondrial bio-
genesis (35), and total mitochondrial volume density were
unchanged as was also observed in skeletal muscles of
mice with dominant-negative mutant of AMPK (36). All of
this suggests that AMPK2 is not essential for determining
and maintaining mitochondrial mass in skeletal and car-
diac muscle. However, it may play a role in cardiac
mitochondrial biogenesis induced by external stimulus, as
was observed in skeletal muscle in response to exercise or
chronic energy depletion (36).
Mitochondrial function also depends on the sensitivity
to ADP and to creatine, the ﬁnal acceptor of high-energy
phosphates in cardiac mitochondria (37). No change in the
sensitivity of respiration to ADP and creatine was observed,
showing that the efﬁciency of cardiac mitochondria in
phosphorylating ADP and producing phosphocreatine was
not affected by AMPK2 loss.
To explain the decreased respiration with preserved
enzyme activities, we compared the respiration rates dur-
ing activation from complex I, II, or III (Figs. 1 and 3; Table
2). Respiration with glutamate plus malate mainly pro-
duces NADH, which activates respiration through com-
plex I, whereas succinate oxidation mainly produces
FADH2, which is further oxidized by complex II. Com-
pared with controls, respiration was lower in AMPK2
/
mice with glutamate plus malate but was normal with
succinate, revealing an inhibition of complex I in these
animals. Interestingly, respiration from G3P, which pro-
duces only FADH2, was normal in AMPK2
/ mice,
whereas it was decreased for NADH-producing substrates:
pyruvate and octanoyl-carnitine. Moreover, respiration
through complex III was unchanged in AMPK2
/ mice.
Despite a 24% decrease in respiration rate through
complex I, complex I activity measured in total heart
extracts was normal in AMPK2
/ mice, independent of
the electron acceptor. This indicated that the activity of
isolated complex I was not affected by AMPK2 deﬁ-
ciency, suggesting an alteration of the in situ regulation of
complex I by cardiolipin. Activity of the complexes of the
respiratory chain, and particularly of complex I, strongly
depends on the surrounding phospholipid environment of
the inner mitochondrial membrane. Cardiolipin is the main
functional phospholipid of the mitochondrial inner mem-
brane, being present almost exclusively in mitochondria
and representing 8–15% of the entire cardiac phospholipid
mass. A 25% lower mitochondrial cardiolipin content was
observed in AMPK2
/ mice. Cardiolipin content is crit-
ical for the adaptation of energy metabolism to demand. It
rises with increased metabolic rate or muscle performance
(38) and plays a key role in the activity of several inner
membrane proteins including complex I (rev. in 39). Both
complex I and III were shown to require cardiolipin, but
although necessary for full complex I activity (40), cardi-
olipin plays a structural rather than catalytic role for
complex III (41). Accordingly, respiration through com-
plex I but not complex III was decreased in AMPK2
/
mice. Interestingly, in CHO cells, similar decrease in
cardiolipin content induces similar alteration in complex I
activity in the respiratory chain without changes in iso-
lated, complex II, complex III and IV, and NADH reductase
activity (31). mi-CK binding in the vicinity of translocase is
dependent on cardiolipin environment (42). It is possible
that the rather small decrease in cardiolipin observed here
was not sufﬁcient to affect mi-CK function and activity.
Examination of cardiac ultrastructure of AMPK2
/
mice revealed abnormal structure of mitochondria of
various sizes arranged in clusters under the sarcolemma
and less in regular rows between myoﬁlaments as in
control hearts. Although unchanged total mitochondrial
volume was in accordance with preserved mitochondrial
enzyme activity and PGC-1 expression, partial relocation
of mitochondria from myoﬁbrillar to subsarcolemmal
space occurred. No evidence of ultrastructural changes
was observed in AMPK KD mutant (12). However, in the
present study, these morphological changes were ob-
served at higher magniﬁcation and could be more pro-
nounced in older animals. Similarly, in CHO cells, an
alteration of mitochondrial ultrastructure is speciﬁcally
associated with reduction in cardiolipin content (31).
Moreover, although to a lower extent, this resembles the
ultrastructural abnormalities of mitochondria in the Barth
syndrome, an X-linked disease. This disease, due to muta-
tions in the tafazzin gene that belongs to the superfamily of
phospholipid acyltransferase, is characterized by a dra-
matic reduction in cardiolipin content and by abnormal
mitochondrial ultrastructure (43).
Cardiolipin is the only phospholipid with four acyl
chains, 80% of which are composed of linoleic acid
(18:26), a polyunsaturated fatty acid of the 6 series. The
decrease in cardiolipin content in AMPK2
/ heart was
accompanied by a signiﬁcant decrease in linoleic acid
content of mitochondrial and whole-heart phospholipids.
The decrease in mitochondrial membrane linoleic acid
observed in this study is due to neither nutritional differ-
ences, because animals received the same chow diet, nor
a systemic effect because the plasma and liver lipid
composition was unchanged. The fact that 1) the linoleic
acid decrease parallels the cardiolipin decrease, 2) cardi-
olipin contains 80% linoleic acid, and 3) the linoleic acid
content in storage lipids was higher suggests that the
decrease in linoleic acid is a consequence rather than a
cause of the cardiolipin decrease in AMPK2-deﬁcient
mice. The lower linoleic acid content in heart compared
with liver of AMPK2
/ mice could be related to the
higher proportion of AMPK1 in liver (4). These animals
are thus characterized by a dysfunction of cardiac cardi-
olipin homeostasis that affects the inner mitochondrial
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drial dysfunction.
Similar decreases in cardiolipin content and complex I
activity were reported after partial inhibition of cardiolipin
synthesis in CHO cells (31). One important rate-limiting
step of de novo cardiolipin synthesis is the initial reaction
catalyzed by CDS (33). In AMPK2
/ mice, expression of
CDS2, the only cardiac isoform (44), is decreased, possibly
explaining the decrease in cardiolipin content. A second
mechanism of cardiolipin biosynthesis is through deacyla-
tion-reacylation, which is catalyzed by phospholipases and
acyltransferases, which are regarded as the principal en-
zymes involved in phospholipid remodeling in mammalian
tissues (33). The acyltransferase ALCAT1 is regulated in
concert with the level of cardiolipin and cardiolipin bio-
synthesis in mammalian heart (32,45). ALCAT1 mRNA
expression was decreased in AMPK2
/ mice like both
CDS2 mRNA and cardiolipin content. All of this suggests
that AMPK is involved in cardiolipin homeostasis at least
at the transcriptional level. Finally, expression of the
mitochondrial fatty acid transporter CPT-1 was also de-
creased in AMPK2-deﬁcient mice. Decreased activation
of CPT-1 because of the lack of AMPK-modulated regula-
tion of malonyl CoA content, together with the downregu-
lation of CPT-1, would have an additive inhibitory effect on
fatty acid oxidation in AMPK2
/ mice.
In summary, selective deﬁciency of AMPK2 causes a
signiﬁcant decrease in maximal mitochondrial respiration,
whether carbohydrates or lipids were used as substrates.
This is due to a defect in the function of complex I of the
respiratory chain within the inner mitochondrial mem-
brane, probably because of the decrease in cardiolipin
content. Interestingly, it has been recently reported that
the diabetic heart, characterized by altered lipid ho-
meostasis and mitochondrial dysfunction, exhibits a dra-
matic decrease in cardiolipin content (46). These ﬁndings
suggest that AMPK plays a critical role in the control of
cardiac phospholipid homeostasis, possibly by modulating
their metabolism through transcriptional machinery. More
work is needed to elucidate the precise mechanisms by
which AMPK may enhance energy production by favoring
cardiolipin synthesis and thus improving the efﬁciency of
the respiratory chain.
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